Evidence map›Paper›PMID 34502448›Full record

ArticleInternational journal of molecular sciences2021

Molecular Network Approach Reveals

András Makkos, Bence Ágg, Zoltán V Varga, Zoltán Giricz, Mariann Gyöngyösi, Dominika Lukovic, Rainer Schulz, Monika Barteková, Anikó Görbe, Péter Ferdinandy

Open access · goldAbstract readValidation Study
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

András MakkosCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary.ORCID 0000-0002-0309-4909
Bence ÁggCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary.ORCID 0000-0002-6492-0426
Zoltán V VargaCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary.ORCID 0000-0002-2758-0784
Zoltán GiriczCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary.ORCID 0000-0003-2036-8665
Mariann GyöngyösiDivision of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-7083-2107
Dominika LukovicDivision of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
Rainer SchulzInstitute of Physiology, Justus Liebig University Giessen, 35392 Giessen, Germany.ORCID 0000-0003-3017-0476
Monika BartekováInstitute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, Dúbravská cesta 9, 84104 Bratislava, Slovakia.ORCID 0000-0002-5210-5184
Anikó GörbeCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary.
Péter FerdinandyCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary.
Semmelweis University · HUMedical University of Vienna · ATJustus-Liebig-Universität Gießen · DESlovak Academy of Sciences · SK

Funding

bilateral funding of the Hungarian (OTKA) and Austrian Science Funds (FWF) FWF I 1277European Union's Horizon 2020 research and innovation programme No 739593Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary framework of the Therapeutic Development thematic programme of the Semmelweis Universi-tyMinistry for Innovation and Technology ÚNKP-19-3-I-SE-60Ministry for Innovation and Technology ÚNKP-20-4-I-SE-7Ministry for Innovation and Technology in Hungary 2020-4.1.1.-TKP2020National Research, Development and Innovation Office of Hungary 2019-1.1.1-PIACI-KFI-2019-00367National Research, Development and Innovation Office of Hungary NVKP-16-1-2016-0017National Research, Development and Innovation Office of Hungary OTKA-FK 134751National Research, Development and Innovation Office of Hungary VEKOP-2.3.2-16-2016-00002New National Excellence Program of the Ministry for Innovation and Technology ÚNKP-20-5
6 · The paper itself

Abstract

Cardioprotective medications are still unmet clinical needs. We have previously identified several cardioprotective microRNAs (termed ProtectomiRs), the mRNA targets of which may reveal new drug targets for cardioprotection. Here we aimed to identify key molecular targets of ProtectomiRs and confirm their association with cardioprotection in a translational pig model of acute myocardial infarction (AMI). By using a network theoretical approach, we identified 882 potential target genes of 18 previously identified protectomiRs. The

Indexed as

Molecular Targeted TherapyAnimalsCardiotonic AgentsIschemic PostconditioningIschemic Preconditioning, MyocardialMicroRNAsMyocardial InfarctionRapamycin-Insensitive Companion of mTOR ProteinRatsSwineCardiotonic AgentsMicroRNAsRapamycin-Insensitive Companion of mTOR ProteincardioprotectionmicroRNAmiRNAnetwork theoryRictorvasculoprotection

Identifiers

PMID34502448
PMCPMC8430799
OpenAlexW3198740619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.